||CB1 antagonist 1
||CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disord
||CB1 inverse agonist 1
||CB1 inverse agonist 1 is an orally active, and specific inverse agonist of the CB1 receptor (IC50s: 7.5 nM and 4100 nM for CB1 and CB2 receptors) with anorexigenic effects.
||Taranabant racemate is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor.
||6-Iodopravadoline (AM630) is an antagonist of CB2 (Ki: 31.2 nM). And it shows 165-fold selectivity more than CB1 receptors.
||Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2.
||BAY 38-7271 has strong neuroprotective properties. BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist. With Kis of 1.85 nM and 5.96 nM for recom
||Rimonabant hydrochloride is a cannabinoid receptor antagonist, binding selectively to central cannabinoid receptors (CB1) with high affinity.
||Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a redu
||SR144528 is an effective and selective antagonist of the CB2 receptor (Ki: 0.6 nM).
||Tedalinab is an effective and selective cannabinoid receptor 2 agonist. Tedalinab has the potential for neuropathic pain and osteoarthritis treatment. Tedalinab has >4700-fold func
||Otenabant hydrochloride (CP-945598) is a competitive, high affinity, selective antagonist of the CB1 receptor (Ki: 0.7 nM).
||AM251 is a effective CB1 receptor antagonist (IC50/Ki: 8 /7.49 nM) that displays 306-fold selectivity over CB2 receptors; also effective GPR55 agonist (EC50: 39 nM).
||AM 281, a cannabinoid antagonist, reduces neurologic dysfunction and mortality rate after cecal ligation and puncture in rats.
||Org 27569, an allosteric modulator of cannabinoid CB1 receptor, can induce a CB1 receptor state that is characterized by decreased inverse agonist affinity and enhanced agonist aff
||Otenabant has been investigated for the treatment of Obesity.
||Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic p
||1. Yangonin is a novel CB₁ receptor ligand, it exhibits affinity for the human recombinant CB₁ receptor. 2. Yangonin could be a valuable candidate for the intervention of NF-κ
||JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
||WIN 55,212-2 Mesylate
||WIN 55, 212-2 (Mesylate) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Kis of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.
||SLV319 has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.
||CB1-IN-1 is a peripherally restricted CB1R antagonist, for CB1R and CB2R with Ki of 0.3 nM and 21 nM,respectively.
||BML-190 is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.
||GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.
||AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor.
||LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM). It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively).
||A-836339 acts as a potent cannabinoid receptor full agonist which has a higher affinity for the peripheral CB2 receptor (Ki = 0.64 nM) over the central CB1 receptor (Ki = 270 nM).
||GW 405833 is an agonist of cannabinoid-2 (CB(2)) receptor-selective
||TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.
||β-Caryophyllene is a CB2 receptor agonist.
||Tetrahydromagnolol can activate cannabinoid (CB) receptors.
||Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile s
||MDA 19 is a specific human CB2 receptor agonist (Ki: 43.3 nM).
||Cannabidiol is GPR55 and weak CB1 antagonist (IC50s: 0.445 and 3.35 μM), CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50: 27.5 μM). It also a weak agonist a